Skip to content

Category: Programme 2 – PISTER

Modeling tumor development and progression: From PDXs to cancer organoids | A colloquium sponsored by SIRIC ILIAD

On October 18th, the French PDX network and the Organoids research group organised, with the support of the SIRIC ILIAD
Lire la suite >

Breast cancers: acting on cells in the tumour environment to treat the cancer?

What if acting on the cells surrounding the tumour could improve the effectiveness of treatments? On 14 September 2022, a
Lire la suite >

Teclistamab: a promising new treatment for multiple myeloma

Last August, Professor Philippe Moreau, haematologist and director of SIRIC ILIAD, published a scientific article in the prestigious New England
Lire la suite >

Welcome to Sara Gandolfi, post-doctoral researcher in cell biology at SIRIC ILIAD!

Since May 2022, Sara Gandolfi has joined the ranks of the SIRIC ILIAD teams as a post-doctoral researcher. She has
Lire la suite >

Immunotherapy in multiple myeloma: focus on bispecific antibodies

Last June, Professors Philippe Moreau and Cyrille Touzeau, both haematologists and researchers at SIRIC ILIAD, published a scientific article in
Lire la suite >

Opening for a postdoctoral position at the CRCI²NA

The Centre de Recherches en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI²NA) offers a postdoctoral position in cell biology. Contract
Lire la suite >

In 2022, the CRCINA evolves and becomes the CRCI²NA

In January 2022, at the end of its five-year mandate, the CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes
Lire la suite >

Cancer research: The importance of SIRICs recognised by the scientific committee of INCa

Following the mid-term evaluation of the SIRICs (SIte de Recherche Intégrée sur le Cancer), the scientific committee of the French
Lire la suite >



Archives SIRIC 2018-2022